Analyzing Niagen Bioscience (NASDAQ:NAGE) and Kimberly-Clark (NASDAQ:KMB)

Kimberly-Clark (NASDAQ:KMB) and Niagen Bioscience (NASDAQ:NAGE) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Profitability

This table compares Kimberly-Clark and Niagen Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kimberly-Clark	11.79%	143.92%	14.21%
Niagen Bioscience	12.39%	17.95%	13.17%

Valuation & Earnings

This table compares Kimberly-Clark and Niagen Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kimberly-Clark	$16.45 billion	2.19	$2.02 billion	$5.88	18.45
Niagen Bioscience	$129.08 million	1.47	$17.38 million	$0.18	13.25

Kimberly-Clark has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Kimberly-Clark, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Kimberly-Clark has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.

Insider & Institutional Ownership

76.3% of Kimberly-Clark shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 0.7% of Kimberly-Clark shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Kimberly-Clark and Niagen Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kimberly-Clark	2	12	4	1	2.21
Niagen Bioscience	0	1	3	1	3.00

Kimberly-Clark currently has a consensus price target of $111.56, indicating a potential upside of 2.81%. Niagen Bioscience has a consensus price target of $10.00, indicating a potential upside of 319.29%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Kimberly-Clark.

Summary

Kimberly-Clark beats Niagen Bioscience on 9 of the 14 factors compared between the two stocks.

About Kimberly-Clark

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company’s Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company’s K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

About Niagen Bioscience

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.